<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287584</url>
  </required_header>
  <id_info>
    <org_study_id>D4904020</org_study_id>
    <secondary_id>JapicCTI-142688</secondary_id>
    <nct_id>NCT02287584</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of DSP-5423P in Patients With Schizophrenia</brief_title>
  <official_title>Confirmatory Study of DSP-5423P in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with
      placebo in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PANSS total score from baseline</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>DSP-5423P Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P 40mg</intervention_name>
    <arm_group_label>DSP-5423P 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P 80mg</intervention_name>
    <arm_group_label>DSP-5423P 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P Placebo</intervention_name>
    <arm_group_label>DSP-5423P Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria

          -  Patients who are aged 18 years or older at informed consent

          -  Patient understands the objectives and procedures of the study and who provide written
             voluntarily consent to participate in the study, etc.

        Exclusion Criteria:

          -  Patients who fall under a contraindication listed in the blonanserin (LONASEN) package
             insert

          -  Patients with Parkinson disease

          -  Patients who previously received blonanserin, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3 Sites</name>
      <address>
        <city>Beijing, Etc.</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>53 Sites</name>
      <address>
        <city>Tokyo, Etc</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>7 Sites</name>
      <address>
        <city>Seoul, Etc.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14 Sites</name>
      <address>
        <city>Kuala Lumpur, Etc.</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9 Sites</name>
      <address>
        <city>Manila, etc.</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Smolensk, Etc</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>6 Sites</name>
      <address>
        <city>Taipei, Etc.</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Poltava, Etc</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

